Literature DB >> 23728855

Development of a sandwich ELISA for the quantification of enterovirus 71.

Shujun Ma1, Qunying Mao, Zhenglun Liang, Cuijuan Zhang, Wenxing Yang, Zhe Sun, Haijiang Zhang, Xinliang Shen, Shengli Bi, Le Sun.   

Abstract

Since 2008, enterovirus 71 (EV71) has been responsible for high-mortality seasonal epidemics of hand, foot and mouth disease in China. Currently many groups in the world are in the process of developing EV71 vaccines to combat this deadly disease. We have developed three EV71-specific monoclonal antibodies, and in this study we report the establishment of a fast and cost-effective sandwich ELISA kit for measurement of virus concentration in EV71 vaccines using a pair of mouse anti-EV71 monoclonal antibodies. The system is specific for EV71 virus, with no cross-reactivity to coxsackievirus A16, H1N1, rabies, and hepatitis A. Using a reference EV71 vaccine standard, the sensitivity of the assay kit was determined to be 0.82 U/ml, with a linear range between 3.75 and 120 U/ml.

Entities:  

Year:  2013        PMID: 23728855      PMCID: PMC3973802          DOI: 10.1007/s10616-013-9588-9

Source DB:  PubMed          Journal:  Cytotechnology        ISSN: 0920-9069            Impact factor:   2.058


  11 in total

1.  Immunoprotection elicited by an enterovirus type 71 experimental inactivated vaccine in mice and rhesus monkeys.

Authors:  Chenghong Dong; Longding Liu; Hongling Zhao; Jingjing Wang; Yun Liao; Xuemei Zhang; Ruixiong Na; Yan Liang; Lichun Wang; Qihan Li
Journal:  Vaccine       Date:  2011-06-29       Impact factor: 3.641

2.  Safety and immunogenicity of a novel human Enterovirus 71 (EV71) vaccine: a randomized, placebo-controlled, double-blind, Phase I clinical trial.

Authors:  Yan-Ping Li; Zheng-Lun Liang; Qiang Gao; Li-Rong Huang; Qun-Ying Mao; Shu-Qun Wen; Yan Liu; Wei-Dong Yin; Rong-Cheng Li; Jun-Zhi Wang
Journal:  Vaccine       Date:  2012-03-15       Impact factor: 3.641

3.  Antigenicity, animal protective effect and genetic characteristics of candidate vaccine strains of enterovirus 71.

Authors:  Qunying Mao; Nan Li; Xiang Yu; Xin Yao; Fengxiang Li; Fengmin Lu; Hui Zhuang; Zhenglun Liang; Junzhi Wang
Journal:  Arch Virol       Date:  2011-10-09       Impact factor: 2.574

4.  High immunogenic enterovirus 71 strain and its production using serum-free microcarrier Vero cell culture.

Authors:  Chia-Chyi Liu; Wei-Cheng Lian; Michael Butler; Suh-Chin Wu
Journal:  Vaccine       Date:  2006-08-02       Impact factor: 3.641

5.  Hand foot and mouth disease due to enterovirus 71 in Malaysia.

Authors:  Kaw Bing Chua; Abdul Rasid Kasri
Journal:  Virol Sin       Date:  2011-08-17       Impact factor: 4.327

6.  Enterovirus 71 infection: An experience in Korea, 2009.

Authors:  Kyung Hyo Kim
Journal:  Korean J Pediatr       Date:  2010-05-31

7.  Formaldehyde-inactivated whole-virus vaccine protects a murine model of enterovirus 71 encephalomyelitis against disease.

Authors:  Kien Chai Ong; Shamala Devi; Mary Jane Cardosa; Kum Thong Wong
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

8.  Generation of neutralizing monoclonal antibodies against Enterovirus 71 using synthetic peptides.

Authors:  Xiuling Li; Chunming Mao; Shujun Ma; Xiaoqing Wang; Zhe Sun; Yao Yi; Minzhuo Guo; Xinliang Shen; Le Sun; Shengli Bi
Journal:  Biochem Biophys Res Commun       Date:  2009-09-30       Impact factor: 3.575

9.  Comparative analysis of the immunogenicity and protective effects of inactivated EV71 vaccines in mice.

Authors:  Qunying Mao; Chenghong Dong; Xiuling Li; Qiang Gao; Zengbing Guo; Xin Yao; Yiping Wang; Fan Gao; Fengxiang Li; Miao Xu; Weidong Yin; Qihan Li; Xinliang Shen; Zhenglun Liang; Junzhi Wang
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

10.  The persistent circulation of enterovirus 71 in People's Republic of China: causing emerging nationwide epidemics since 2008.

Authors:  Xiaojuan Tan; Xueyong Huang; Shuangli Zhu; Hui Chen; Qiuli Yu; Haiyan Wang; Xixiang Huo; Jianhui Zhou; Yan Wu; Dongmei Yan; Yong Zhang; Dongyan Wang; Aili Cui; Hongqiu An; Wenbo Xu
Journal:  PLoS One       Date:  2011-09-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.